IceCure Medical Receives 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance

summarizeSummary

IceCure Medical received a 180-day extension from Nasdaq to regain compliance with the minimum bid price rule, avoiding immediate delisting but signaling ongoing challenges.

check_boxKey Events

• Nasdaq Compliance Extension Granted

  IceCure Medical received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, extending the deadline to November 9, 2026.

• Previous Non-Compliance

  The company failed to regain compliance during the initial 180-day period, which ended on May 11, 2026, after first being notified on November 12, 2025.

• Potential Reverse Share Split

  IceCure Medical indicated its intention to cure the deficiency, potentially by effecting a reverse share split if necessary.

• No Immediate Delisting

  The notification has no immediate effect on the listing or trading of the company's ordinary shares on the Nasdaq Capital Market.

auto_awesomeAnalysis

IceCure Medical has been granted a critical 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement, pushing the deadline to November 9, 2026. This extension provides a temporary reprieve from potential delisting, which would severely impact the company's visibility and liquidity, especially for a micro-cap company already facing a 'going concern' warning. The company's stated intention to potentially effect a reverse share split to cure the deficiency highlights the severity of the situation and could be viewed negatively by investors.